The #RECOVAC IR study: the immune response and safety of the mRNA-1273 #COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. #CKD#ESKD#openaccess@NDTsocial
https://t.co/xHvHpY4iKm
Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial @JASN_News
IgA Nephropathy: Review ca. 2021 from @Nephronpower#Nephpearls
📌 4-hit hypothesis
📌 IgA Nephropathy vs IgA Vasculitis with nephritis
👉 https://t.co/OOw8ZAJqPP
⚠️TWO DIFFERENT #COVID19 PANDEMICS—Many think with cases dropping that pandemic is nearly over. But truth is, there are now 2 different #SARSCoV2 pandemics diverging—old strain is waning, while the more contagious #B117 strain is dominating. We will be soon slammed very hard. 🧵
How do you communicate the expected lifetime benefits of HF therapies?
New data in @TheLancet from 3 RCTs (#EMPHASISHF#PARADIGMHF#DAPAHF) estimate up to *6 years* of survival gains.
Combination ARNI+BB+MRA+SGLT2i = new therapeutic standard in HFrEF.
📎https://t.co/xd23cW9Ovp
⚠️Sweden is not a “success”. And it should be compared to its Scandinavian sister countries because of its shared socioeconomic similarities including Scandinavian healthcare system (and being Nordic EU Schengen countries that are not Euro currency). #COVID19